Boston Scientific Corp. has joined a crowded European transcatheter aortic heart valve replacement market with the launch of its Lotus TAVR system at select centers. The firm announced the CE mark and initial limited launch of the device Oct. 28, with plans to accelerate commercial site expansion as physicians and centers become fully trained.
Edwards Lifesciences Corp.’s Sapien and Medtronic PLC’s CoreValve lead the European TAVR market, but at least five other companies with competitive devices claim next-generation procedural advantages.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?